Ulf Andersson

List of Publications by Year
in descending order

129 papers	22,609 citations	18465 62 h-index	16164 124 g-index
139 all docs	139 docs citations	139 times ranked	17341 citing authors

#	Article	IF	Citations
1	HMG-1 as a Late Mediator of Endotoxin Lethality in Mice. Science, 1999, 285, 248-251.	6.0	3,807
2	High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes. Journal of Experimental Medicine, 2000, 192, 565-570.	4.2	1,306
3	HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection. Annual Review of Immunology, 2011, 29, 139-162.	9.5	1,230
4	Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit. Science, 2011, 334, 98-101.	6.0	1,158
5	Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 296-301.	3.3	1,085
6	A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11942-11947.	3.3	705
7	Novel role of PKR in inflammasome activation and HMGB1 release. Nature, 2012, 488, 670-674.	13.7	672
8	HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nature Reviews Rheumatology, 2012, 8, 195-202.	3.5	596
9	Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. Journal of Experimental Medicine, 2012, 209, 1519-1528.	4.2	590
10	Assessment of Cytokines by Immunofluorescence and the Paraformaldehyde-Saponin Procedure. Immunological Reviews, 1991, 119, 65-93.	2.8	462
11	The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of Leukocyte Biology, 2013, 93, 865-873.	1.5	449
12	Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. European Journal of Immunology, 2004, 34, 1503-1512.	1.6	379
13	Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1). Molecular Medicine, 2012, 18, 250-259.	1.9	378
14	Strategies of Anti-Cytokine Monoclonal Antibody Development: Immunoassay of IL-10 and IL-5 in Clinical Samples. Immunological Reviews, 1992, 127, 5-24.	2.8	365
15	Reflex Principles of Immunological Homeostasis. Annual Review of Immunology, 2012, 30, 313-335.	9.5	348
16	Targeting Inflammation Driven by HMGB1. Frontiers in Immunology, 2020, 11, 484.	2.2	320
17	Neural reflexes in inflammation and immunity. Journal of Experimental Medicine, 2012, 209, 1057-1068.	4.2	308
18	JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3068-3073.	3.3	300

#	Article	IF	Citations
19	Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1. Molecular Medicine, 2003, 9, 37-45.	1.9	295
20	MD-2 is required for disulfide HMGB1â€“dependent TLR4 signaling. Journal of Experimental Medicine, 2015, 212, 5-14.	4.2	295
21	High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Molecular Medicine, 2015, 21, S6-S12.	1.9	275
22	The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. Journal of Leukocyte Biology, 2009, 86, 655-662.	1.5	263
23	High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis. Arthritis and Rheumatism, 2002, 46, 2598-2603.	6.7	261
24	Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism, 1997, 40, 865-874.	6.7	246
25	Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opinion on Therapeutic Targets, 2018, 22, 263-277.	1.5	225
26	High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Seminars in Immunology, 2018, 38, 40-48.	2.7	221
27	HMGB1 as a DNA-binding cytokine. Journal of Leukocyte Biology, 2002, 72, 1084-91.	1.5	215
28	Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. Molecular Medicine, 2020, 26, 42.	1.9	176
29	Bacterial Toxin-Induced Cytokine Production Studied at the Single-Cell Level. Immunological Reviews, 1992, 127, 69-96.	2.8	173
30	Î±7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation by Preventing Mitochondrial DNA Release. Molecular Medicine, 2014, 20, 350-358.	1.9	169
31	Simultaneous production of interleukin 2, interleukin 4 and interferon-Î³ by activated human blood lymphocytes. European Journal of Immunology, 1990, 20, 1591-1596.	1.6	167
32	High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Research and Therapy, 2008, 10, 209.	1.6	164
33	High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis and Rheumatism, 2003, 48, 1693-1700.	6.7	161
34	Pooled Human IgG Modulates Cytokine Production in Lymphocytes and Monocytes. Immunological Reviews, 1994, 139, 21-42.	2.8	156
35	Systemic anti-tumor necrosis factor Î± therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor Î± synthesis. Arthritis and Rheumatism, 2000, 43, 2391-2396.	6.7	154
36	Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Molecular Medicine, 2003, 9, 37-45.	1.9	148

#	Article	IF	Citations
37	Regulation of HMGB1 release by inflammasomes. Protein and Cell, 2013, 4, 163-167.	4.8	144
38	Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates pain-like behavior in experimental arthritis. Pain, 2014, 155, 1802-1813.	2.0	141
39	C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood, 2016, 128, 2218-2228.	0.6	130
40	High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Research and Therapy, 2011, 13, R136.	1.6	117
41	TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO Journal, 2012, 32, 86-99.	3.5	117
42	Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1602-1607.	3.3	113
43	Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. European Journal of Immunology, 1992, 22, 2617-2623.	1.6	112
44	Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight, 2016, 1, .	2.3	112
45	The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 141-148.	0.9	104
46	Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis and Rheumatism, 2004, 50, 1586-1594.	6.7	102
47	Monoclonal Anti-HMGB1 (High Mobility Group Box Chromosomal Protein 1) Antibody Protection in Two Experimental Arthritis Models. Molecular Medicine, 2011, 17, 1039-1044.	1.9	101
48	Regulation of Posttranslational Modifications of HMGB1 During Immune Responses. Antioxidants and Redox Signaling, 2016, 24, 620-634.	2.5	98
49	HMGB1 in Sepsis. Scandinavian Journal of Infectious Diseases, 2003, 35, 577-584.	1.5	97
50	A novel high mobility group box 1 neutralizing chimeric antibody attenuates drugâ€induced liver injury and postinjury inflammation in mice. Hepatology, 2016, 64, 1699-1710.	3.6	96
51	A Systematic Nomenclature for the Redox States of High Mobility Group Box (HMGB) Proteins. Molecular Medicine, 2014, 20, 135-137.	1.9	94
52	High Mobility Group Box Protein 1 (HMGB1)-Partner Molecule Complexes Enhance Cytokine Production by Signaling Through the Partner Molecule Receptor. Molecular Medicine, 2012, 18, 224-230.	1.9	92
53	High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis and Rheumatism, 2003, 48, 876-881.	6.7	82
54	TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Annals of the Rheumatic Diseases, 2013, 72, 1390-1399.	0.5	81

#	Article	IF	Citations
55	Systemic HMGB1 Neutralization Prevents Postoperative Neurocognitive Dysfunction in Aged Rats. Frontiers in Immunology, 2016, 7, 441.	2.2	81
56	Expression of Concern: The functions of <scp>HMGB</scp>1 depend on molecular localization and postâ€translational modifications. Journal of Internal Medicine, 2014, 276, 420-424.	2.7	80
57	Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis and Rheumatism, 2005, 52, 3880-3889.	6.7	79
58	Identification of a brainstem locus that inhibits tumor necrosis factor. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29803-29810.	3.3	76
59	Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Molecular Medicine, 2019, 25, 13.	1.9	75
60	Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB Journal, 2010, 24, 570-578.	0.2	74
61	Expression of Concern: <scp>HMGB</scp>1 mediates splenomegaly and expansion of splenic <scp>CD</scp>11b+ <scp>L</scp>yâ€6<scp>C</scp>^{high} inflammatory monocytes in murine sepsis survivors. Journal of Internal Medicine, 2013, 274, 381-390.	2.7	74
62	Blood pressure regulation by CD4+ lymphocytes expressing choline acetyltransferase. Nature Biotechnology, 2016, 34, 1066-1071.	9.4	74
63	Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity, 2021, 54, 454-467.e6.	6.6	74
64	Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. European Journal of Immunology, 1996, 26, 1-9.	1.6	68
65	Gamma-Interferon is Produced by CD3+ and CD3- Lymphocytes. Immunological Reviews, 1987, 97, 51-65.	2.8	63
66	Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2007, 56, 674-687.	6.7	58
67	High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology, 2009, 214, 303-309.	0.8	57
68	High Mobility Group Box Chromosomal Protein 1 (HMGB1) Is an Antibacterial Factor Produced by the Human Adenoid. Pediatric Research, 2002, 52, 148-154.	1.1	55
69	Identification of individual tumor necrosis factor/ cachectin-producing cells after lipopolysaccharide induction. European Journal of Immunology, 1988, 18, 983-988.	1.6	52
70	A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers, 2009, 14, 572-586.	0.9	51
71	HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheumatic Disease Clinics of North America, 2004, 30, 627-637.	0.8	49
72	Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis and Rheumatism, 2010, 62, 2963-2972.	6.7	49

#	Article	IF	Citations
73	Adenylyl Cyclase 6 Mediates Inhibition of TNF in the Inflammatory Reflex. Frontiers in Immunology, 2018, 9, 2648.	2.2	49
74	Computerized assessment of production of multiple human cytokines at the single-cell level using image analysis. Journal of Leukocyte Biology, 1996, 59, 287-295.	1.5	47
75	Pivotal Advance: Inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. Journal of Leukocyte Biology, 2008, 83, 31-38.	1.5	45
76	High Systemic Levels of the Cytokine-Inducing HMGB1 Isoform Secreted in Severe Macrophage Activation Syndrome. Molecular Medicine, 2014, 20, 538-547.	1.9	45
77	HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors. Molecular Medicine, 2015, 21, 951-958.	1.9	45
78	Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-Guerin. Journal of Urology, 1996, 156, 536-541.	0.2	44
79	Introduction: HMGB1 in inflammation and innate immunity. Journal of Internal Medicine, 2011, 270, 296-300.	2.7	44
80	The cholinergic anti-inflammatory pathway alleviates acute lung injury. Molecular Medicine, 2020, 26, 64.	1.9	43
81	Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms. Journal of Innate Immunity, 2018, 10, 215-227.	1.8	41
82	Immunomodulatory Drugs Regulate HMGB1 Release from Activated Human Monocytes. Molecular Medicine, 2010, 16, 343-351.	1.9	40
83	Dynamics of Early Synovial Cytokine Expression in Rodent Collagen-Induced Arthritis. American Journal of Pathology, 2001, 158, 491-500.	1.9	39
84	HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. Journal of Leukocyte Biology, 2007, 81, 129-136.	1.5	39
85	Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Research and Therapy, 2008, 10, R1.	1.6	37
86	Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. Arthritis Research and Therapy, 2007, 9, R35.	1.6	36
87	Dissociation between cytokine mRNA expression and protein production in shigellosis. European Journal of Immunology, 1996, 26, 1130-1138.	1.6	35
88	Upregulated Local Cytokine Production in Recurrent Tonsillitis Compared with Tonsillar Hypertrophy. Acta Oto-Laryngologica, 1995, 115, 689-696.	0.3	34
89	Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients â€“ a prospective clinical study. Arthritis Research and Therapy, 2008, 10, R33.	1.6	34
90	HMGB1 released from nociceptors mediates inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	34

#	Article	IF	Citations
91	Expression of Concern: The haptoglobin beta subunit sequesters <scp>HMGB</scp>1 toxicity in sterile and infectious inflammation. Journal of Internal Medicine, 2017, 282, 76-93.	2.7	33
92	The Production of Immunoregulatory Cytokines is Localized to the Extrafollicular Area of Human Tonsils. Acta Oto-Laryngologica, 1996, 116, 477-485.	0.3	32
93	Post-Translational Modification of HMGB1 Disulfide Bonds in Stimulating and Inhibiting Inflammation. Cells, 2021, 10, 3323.	1.8	32
94	HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. Journal of Internal Medicine, 2004, 255, 318-319.	2.7	31
95	Tumor Necrosis Factor, Interleukin 11, and Leukemia Inhibitory Factor Produced by Langerhans Cells in Langerhans Cell Histiocytosis. Journal of Pediatric Hematology/Oncology, 2004, 26, 706-711.	0.3	29
96	Identification of ethyl pyruvate as a NLRP3 inflammasome inhibitor that preserves mitochondrial integrity. Molecular Medicine, 2018, 24, 8.	1.9	29
97	Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndromeâ€“Hemophagocytic Lymphohistiocytosis. Journal of Rheumatology, 2021, 48, 1596-1602.	1.0	26
98	Redox modifications of cysteine residues regulate the cytokine activity of HMGB1. Molecular Medicine, 2021, 27, 58.	1.9	25
99	Characterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis. Antioxidants and Redox Signaling, 2016, 24, 605-619.	2.5	23
100	HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation. Blood, 2022, 139, 3181-3193.	0.6	23
101	TLR4-dependant pro-inflammatory effects of HMGB1 on human adipocyte. Adipocyte, 2016, 5, 384-388.	1.3	21
102	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2019, 16, 45.	3.1	21
103	Serological Follow-up after Treatment of Borrelia Arthritis and Acrodermatitis Chronica Atrophicans. Scandinavian Journal of Infectious Diseases, 1994, 26, 339-347.	1.5	20
104	Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis. Annals of the Rheumatic Diseases, 2007, 66, 1656-1660.	0.5	20
105	Pro-Inflammatory Cytokines Produced by Growth Plate Chondrocytes May Act Locally to Modulate Longitudinal Bone Growth. Hormone Research in Paediatrics, 2012, 77, 180-187.	0.8	18
106	Hyperinflammation: On the pathogenesis and treatment of macrophage activation syndrome. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2717-2722.	0.7	17
107	Phenotypic characterization of individual interferon-Î³-producing cells after OKT3 antibody activation. European Journal of Immunology, 1986, 16, 1457-1460.	1.6	16
108	Immunization Elicits Antigen-Specific Antibody Sequestration in Dorsal Root Ganglia Sensory Neurons. Frontiers in Immunology, 2018, 9, 638.	2.2	15

#	Article	IF	Citations
109	Neurons Are a Primary Driver of Inflammation via Release of HMGB1. Cells, 2021, 10, 2791.	1.8	13
110	Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm. Molecular Medicine, 2022, 28, 57.	1.9	13
111	Biphasic Release of the Alarmin High Mobility Group Box 1 Protein Early After Trauma Predicts Poor Clinical Outcome. Critical Care Medicine, 2019, 47, e614-e622.	0.4	11
112	Prolonged elevation of plasma HMGB1 is associated with cognitive impairment in intensive care unit survivors. Intensive Care Medicine, 2020, 46, 811-812.	3.9	11
113	Identification of Rat IL-1Î², IL-2, IFN-Î³ and TNF-Î± in Activated Splenocytes by Intracellular Immunostaining. Biotechnic and Histochemistry, 2000, 75, 101-109.	0.7	10
114	A new approach to rheumatoid arthritis: treating inflammation with computerized nerve stimulation. Cerebrum: the Dana Forum on Brain Science, 2012, 2012, 3.	0.1	8
115	Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome. Molecular Medicine, 2021, 27, 48.	1.9	7
116	HMGB1 is a critical molecule in the pathogenesis of Gram-negative sepsis. Journal of Intensive Medicine, 2022, 2, 156-166.	0.8	6
117	Emetine Di-HCl Attenuates Type 1 Diabetes Mellitus in Mice. Molecular Medicine, 2016, 22, 585-596.	1.9	5
118	Molecular basis of applied biological therapeutics. Journal of Internal Medicine, 2011, 269, 2-7.	2.7	4
119	Expression of Concern to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Molecular Medicine, 2020, 26, 18.	1.9	3
120	TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO Journal, 2013, 32, 172-172.	3.5	2
121	Title is missing!. Arthritis Research, 2005, 7, P85.	2.0	1
122	Famotidine exerts antiâ€inflammatory effects via a vagus nerveâ€dependent mechanism. FASEB Journal, 2022, 36, .	0.2	1
123	Immunomodulatory drugs can inhibit the extracellular release of HMGB1 from cultured human monocytes. Annals of the Rheumatic Diseases, 2010, 69, A36-A37.	0.5	0
124	Interleukin 1Â and TLR ligands give enhanced cytokine production by their interaction with HMGB1. Annals of the Rheumatic Diseases, 2010, 69, A38-A38.	0.5	0
125	Successful therapy with anti-HMGB1 monoclonal antibodies in two separate experimental arthritis models. Annals of the Rheumatic Diseases, 2011, 70, A77-A78.	0.5	0
126	HMGB1-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Annals of the Rheumatic Diseases, 2012, 71, A80.1-A80.	0.5	0

#	Article	IF	Citations
127	HMGB1 mediates muscle fatigue via TLR4 - a possible mechanism for muscle fatigue in patients with inflammatory myopathies. Annals of the Rheumatic Diseases, 2012, 71, A42.2-A43.	0.5	0
128	Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. Journal of General Physiology, 2012, 140, i3-i3.	0.9	0
129	Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Molecular Medicine, 2020, 26, 17.	1.9	0